abstract |
Heterobifunctional small molecules including anaplastic lymphoma kinase (ALK) ligand conjugated to a degradation/disruption tag through a linker, which selectively degrade/disrupt ALK, ALK fusion proteins, and/or ALK mutant proteins, and compositions and methods of using such degraders/disruptors to treat ALK-mediated cancer are provided. |